Texas Attorney General Takes Legal Action Against Tylenol Manufacturers Over Autism Spectrum Allegations

Legal Action
Ken Paxton, a Trump ally seeking election to US Senate, accused the drug companies of hiding safety concerns of acetaminophen

The top legal official in Texas Ken Paxton is suing the manufacturers of Tylenol, asserting the corporations hid alleged dangers that the medication created to children's cognitive development.

This legal action comes four weeks after Donald Trump publicized an unproven link between using Tylenol - referred to as paracetamol - throughout gestation and autism in young ones.

Paxton is filing suit against Johnson & Johnson, which formerly manufactured the medication, the only pain reliever approved for women during pregnancy, and the current manufacturer, which now manufacturers it.

In a declaration, he claimed they "misled consumers by profiting off of suffering and marketing drugs regardless of the dangers."

The manufacturer asserts there is lacking scientific proof linking Tylenol to autism.

"These corporations deceived for years, deliberately risking countless individuals to boost earnings," the attorney general, from the Republican party, said.

Kenvue commented that it was "seriously troubled by the perpetuation of misinformation on the reliability of paracetamol and the potential impact that could have on the welfare of women and children in America."

On its website, the company also stated it had "regularly reviewed the pertinent research and there is no credible data that demonstrates a verified association between using acetaminophen and autism."

Groups acting on behalf of physicians and healthcare providers share this view.

The leading OB-GYN organization has stated acetaminophen - the key substance in Tylenol - is a restricted selection for women during pregnancy to address discomfort and fever, which can create significant medical dangers if not addressed.

"In multiple decades of studies on the use of acetaminophen in gestation, no reliable research has conclusively proven that the usage of acetaminophen in any period of pregnancy results in neurological conditions in offspring," the group stated.

The lawsuit mentions recent announcements from the previous government in claiming the medication is allegedly unsafe.

In recent weeks, Trump raised alarms from health experts when he told pregnant women to "resist strongly" not to take acetaminophen when unwell.

Federal regulators then published an announcement that physicians should consider limiting the use of acetaminophen, while also mentioning that "a causal relationship" between the medication and autism in minors has remains unverified.

Health Secretary Kennedy, who supervises the FDA, had vowed in spring to undertake "comprehensive study program" that would identify the origin of autism in a short period.

But experts advised that finding a single cause of autism - believed by scientists to be the result of a complicated interplay of inherited and surrounding conditions - would prove challenging.

Autism spectrum disorder is a type of permanent neurological difference and condition that impacts how persons perceive and engage with the world, and is diagnosed using medical professional evaluations.

In his court filing, Paxton - aligned with the former president who is seeking US Senate - alleges Kenvue and J&J "deliberately disregarded and attempted to silence the research" around paracetamol and autism.

The case aims to force the corporations "remove any commercial messaging" that states Tylenol is safe for pregnant women.

This legal action mirrors the complaints of a assembly of parents of minors with autism spectrum disorder and attention deficit hyperactivity disorder who filed suit against the manufacturers of Tylenol in recently.

A federal judge rejected the legal action, stating investigations from the family's specialists was not conclusive.

Jose Hurst
Jose Hurst

Elara is a seasoned journalist with a passion for uncovering stories that matter, bringing years of experience in digital media and reporting.